Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Reference9 articles.
1. Mullard, A. mRNA-based drug approaches phase I milestone. Nat. Rev. Drug Discov. 15, 595 (2016).
2. Chien, K. R., Zangi, L. & Lui, K. O. Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine. Cold Spring Harb. Perspect. Med. 5, a014035 (2014).
3. Yla-Herttuala, S., Bridges, C., Katz, M. G. & Korpisalo, P. Angiogenic gene therapy in cardiovascular diseases: dream or vision? Eur. Heart J. 38, 1365–1371 (2017).
4. Xie, W., Chen, B. & Wong, J. Evolution of the market for mRNA technology. Nat. Rev. Drug Discov. 20, 735–736 (2021).
5. Zangi, L. et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 31, 898–907 (2013).
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献